Protein Synthesis Inhibitors

Contact Hour(s): 

2 Contact Hours including 2 Advanced Pharmacology Hours

Author:

Mariya Rizwan, PharmD

This peer-reviewed course is applicable for the following professions:

Advanced Practice Registered Nurse (APRN), Certified Nurse Midwife, Certified Nurse Practitioner, Certified Registered Nurse Anesthetist (CRNA), Certified Registered Nurse Practitioner, Clinical Nurse Specialist (CNS), Licensed Practical Nurse (LPN), Licensed Vocational Nurses (LVN), Midwife (MW), Nursing Student, Registered Nurse (RN), Registered Nurse Practitioner

Accreditations: 

The American Nurses Credentialing Center (ANCC)

State Approvals:

Alabama, Provider #ABNP1485; California BRN Provider #CEP # 13509; Kentucky Board of Nursing Provider #7-0085; Florida Board of Nursing Provider 50-353

Course Description:

This course discusses protein synthesis inhibitors and their pharmacology in detail to educate healthcare professionals.

Outcomes:

≥ 92% of participants will know comprehensive knowledge about protein synthesis inhibitors, including their mechanisms of action, classifications, indications, antimicrobial spectrum, pharmacokinetics, potential side effects, toxicity, drug interactions, contraindications, and patient-specific considerations.

Objectives:

After completing this continuing education course, the participant will be able to:

1. Describe the mechanism of action and classify each group of protein synthesis inhibitors.
2. Summarize indications and antimicrobial spectrum for each group of protein synthesis inhibitors.
3. Identify the side effects, toxicity, and dosage for each group of protein synthesis inhibitors.
4. Outline the specific patient parameters that should be assessed before administering each group of protein synthesis inhibitors.
5. Explain the drug interactions, warnings, healthcare considerations, and contraindications for each protein synthesis inhibitor.

Disclosures:

CEUFast Inc. and the course planning team for this educational activity do not have any relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.